Skip to main content

Table 2 Different treatment combination and median duration of response

From: Apatinib for advanced sarcoma: results from multiple institutions’ off-label use in China

Target therapy Patient number (N) Best responsea Median (average) DR (months)
Apatinib alone 44 (78.6%) PR 3.8 (5.4)
Apatinib+everolimus 7 (12.5%) PR 8.5 (7.3)
Apatinib+GTb 5 (8.9%) PR 8.5 (7.3)
  1. aPR partial response, SD stable disease according to RECIST 1.1
  2. bGT chemo-protocol combined with gemcitabine 1000 mg/m2 d1,8 and docetaxel 75 mg/m2 d8 once every 21 days